SalMar ASA SALM
Oslo Børs · Consumer Defensive · Farm Products
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for SalMar
| NOK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 20,070 | 28,099 | 26,318 | 27,343 |
| EBITDA | 5,927 | 9,954 | 7,218 | 5,103 |
| Net income | 3,312 | 3,203 | 2,969 | 1,105 |
| Balance sheet | ||||
| Equity | 19,356 | 19,901 | 17,926 | 17,745 |
| Total debt | 23,217 | 15,738 | 19,012 | 23,309 |
| Cash | 2,558 | 621 | 331 | 560 |
| Net debt | 20,659 | 15,117 | 18,681 | 22,749 |
| Ratios and per share | ||||
| EBITDA margin | 29.5% | 35.4% | 27.4% | 18.7% |
| Profit margin | 16.5% | 11.4% | 11.3% | 4.0% |
| Return on equity | 17.1% | 16.1% | 16.6% | 6.2% |
| Earnings/share (NOK) | 22.82 | 24.31 | 22.51 | 8.17 |
| Book value/share (NOK) | 133.37 | 151.04 | 135.88 | 131.13 |
| Shares outstanding (M) | 145 | 132 | 132 | 135 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Quarterly figures from the reports
BetaFrom the company's own reports: 48 reports read by AI, every figure checked against the report's page and arithmetic.
Source: the Q3 2026 report, page 12, published 2026-11-03.
| Quarter | Revenue | Operating profit | Profit | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 2026 | 8,660 | 2,210 | 1,384 | 10.20 | … | Q3 2026, p. 12 |
| Q2 2026 | 7,612 | 1,023 | 367 | 2.70 | … | Q2 2026, p. 12 |
| Q1 2026 | 6,501 | 858 | 569 | 4.20 | … | Q1 2026, p. 11 |
| Q4 2025 | 8,176 | 1,748 | 959 | 7.10 | … | Q4 2025, p. 12 |
| Q3 2025 | 7,850 | 953 | 305 | 2.30 | … | Q3 2025, p. 12 |
| Q2 2025 | 6,175 | 514 | 196 | 1.50 | … | Q2 2025, p. 13 |
| Q1 2025 | 5,193 | −299 | −355 | −2.70 | … | Q1 2025, p. 12 |
| Q4 2024 | 7,876 | 1,322 | 1,004 | 7.60 | … | Q4 2024, p. 13 |
| Q3 2024 | 6,158 | 1,178 | 285 | 2.20 | … | Q3 2024, p. 13 |
| Q2 2024 | 5,838 | 1,393 | 858 | 6.50 | … | Q2 2024, p. 12 |
| Q1 2024 | 6,555 | 1,512 | 821 | 6.20 | … | Q1 2024, p. 11 |
| Q4 2023 | 8,019 | 1,275 | 1,318 | 10.00 | … | Q4 2023, p. 17 |
Amounts in NOK million, EPS in NOK. Each quarter as first reported, as a backtest would have seen it. Adjusted EPS (without one-off items) is shown once the one-off items have been checked against the companies' own adjusted figures.
One-off items in the reports
- 2026-09-30 Fair value adjustment related to biological assets in associates and joint ventures, net of tax, adjusted out of adjusted EPS (profit effect shown as positive): +145.0 NOK million (Q3 2026, p. 26)
- 2026-09-30 Change in fair value of biological assets (unrealised), excluded from operational EBIT: +721.0 NOK million (Q3 2026, p. 19)
- 2026-09-30 Litigation and legal claims: −4.0 NOK million (Q3 2026, p. 12)
- 2026-09-30 Onerous contracts, excluded from operational EBIT: −15.0 NOK million (Q3 2026, p. 12)
- 2026-09-30 Production fee, excluded from operational EBIT: −116.0 NOK million (Q3 2026, p. 12)
- 2026-09-30 Change in fair value of European Salmon Futures: −8.0 NOK million (Q3 2026, p. 19)
- 2026-09-30 Fair value adjustment on biological assets included in cost of goods sold due to business combinations, excluded from operational EBIT: −50.0 NOK million (Q3 2026, p. 19)
- 2026-09-30 Change in fair value of cross-currency interest rate swaps: +74.0 NOK million (Q3 2026, p. 19)
Found by AI and still being validated: hover for the report's own words.
Sign in for free to open each report on the page a figure comes from.
Extracted by an AI model from the reports and can be wrong. Not investment advice.
Key figures
| P/E | 70.1 |
| P/B | 4.4 |
| EV / EBITDA | 19.6 |
| Net debt / EBITDA | 4.5 |
| Return on equity | 6.2% |
| Profit margin | 4.0% |
| Beta 1Y | 0.45 |
| Revenue growth 1Y | +3.9% |
| Revenue CAGR 3Y | +10.9% |
| Earnings/share CAGR 3Y | −29.0% |
| ROE avg. 3Y | 13.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
| 2026 | 10.00 |
| 2025 | 22.00 |
| 2024 | 35.00 |
| 2023 | 20.00 |
| 2022 | 20.00 |
Not investment advice. Figures may contain errors from the data source.